Globus Medical, Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023; unaudited results. Globus develops and sells musculoskeletal medical devices and enabling technologies, including surgical robotics, in the U.S. and internationally.
Financial results
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Net sales | $291.6m | $263.6m | $568.3m | $494.2m |
| Gross profit | $215.1m | $195.2m | $421.0m | $366.6m |
| Operating income | $66.2m | $67.8m | $122.6m | $114.2m |
| Net income | $57.7m | $54.6m | $106.8m | $92.7m |
| Diluted EPS | $0.57 | $0.53 | $1.05 | $0.90 |
| Operating cash flow | Not separately stated | Not separately stated | $88.3m | $81.6m |
- Q2 sales increased 10.6%; six-month sales increased 15.0%. Q2 gross margin was approximately 73.8% versus 74.0%; operating margin was 22.7% versus 25.7%.
- For the first six months, gross margin was approximately 74.1% versus 74.2%; operating margin was 21.6% versus 23.1%. Six-month net margin was approximately 18.8% in both years.
- Q2 sales by product category: Musculoskeletal Solutions $256.9m (+9.7%); Enabling Technologies $34.8m (+18.2%). For the first half, the categories grew 12.6% and 40.6%, respectively.
- At June 30, cash and cash equivalents were $306.5m and marketable securities totaled $697.9m. Current assets were $1.210bn versus current liabilities of $155.2m. Total liabilities were $227.4m; the company reported no borrowings on its revolving facility, which expired August 2, 2023.
- Six-month capital expenditures were $33.9m. Cash and cash equivalents increased $156.0m during the period, to $306.5m.
Changes and management commentary
- Revenue growth reflected increased spine product sales, including robotic spine instruments, market penetration in existing territories, and higher enabling-technology sales. Six-month U.S. sales rose 13.7%; international sales rose 22.3%.
- Operating income declined 2.3% in Q2 despite higher revenue. Q2 R&D rose 22.7% and SG&A rose 12.5%; both increased primarily with personnel costs and investment in product development. Management also cited higher bad-debt and meeting expenses in Q2 SG&A.
- Q2 other income was $8.5m, up from $2.8m, mainly due to higher interest income from increased yields on marketable securities. A $2.7m net litigation benefit reflected receipt of a legal settlement. Acquisition-related costs were $5.7m, including merger costs and unfavorable changes in the fair value of contingent acquisition liabilities.
- Management said cash, cash flows and marketable securities should provide sufficient liquidity for foreseeable needs, while noting additional liquidity could be required as the company executes its strategy. Planned uses include working capital, R&D, surgical-set investment, sales-force expansion and potential acquisitions.
Outlook, risks and unusual items
- No quantitative earnings or revenue guidance is provided. Management expects continued investment in surgical sets, product development, sales-force growth and international expansion. It reports that the business is generally not seasonal, but procedure timing and capital-budget cycles can affect sales.
- The proposed NuVasive merger had stockholder approval, but remained subject to regulatory and other closing conditions. The FTC issued a Second Request in May 2023, extending the HSR review period; the company expected closing in Q3 2023. Risks include delay or failure to close, transaction and integration costs, disruption to employees and commercial relationships, and failure to realize anticipated synergies.
- The company reported slight supplier delays but no meaningful sales-order backlog. It cautioned that prolonged COVID-19 disruption could create one. Inventory rose to $335.6m from $299.0m at year-end; six-month operating cash flow included a $38.7m inventory outflow.
- A patent-infringement suit brought by Moskowitz Family LLC seeks damages and injunctive relief. The company said the outcome and potential loss range could not be determined and recorded no liability as of June 30. The filing also notes that legal matters could materially affect earnings, financial position or cash flows.
- Management stated disclosure controls were effective as of June 30, 2023, with no material changes in internal control over financial reporting during the quarter.
Key facts for investors to verify
- Merger regulatory status, closing conditions, total transaction costs and integration progress.
- Whether sales growth translates into improved operating margins as R&D, SG&A and merger-related expenses rise.
- Inventory levels, supplier constraints, and conversion of reported earnings into operating cash flow.
- Liquidity and investment portfolio composition, including marketable-security values and the post-expiration status of the revolving credit facility.
- Developments in the patent litigation and other contingencies, including any changes to estimated exposure.